- Conditions
- CNS Lesion, Blood Brain Barrier Defect
- Interventions
- P03277, Gadobenate dimeglumine, MRI
- Drug · Device
- Lead sponsor
- Guerbet
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 312 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2018
- U.S. locations
- 10
- States / cities
- Chicago, Illinois • Boston, Massachusetts • Farmington Hills, Michigan + 6 more
Source: ClinicalTrials.gov public record
Updated Oct 24, 2021 · Synced May 21, 2026, 6:55 PM EDT